Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A
19. März 2024 08:00 ET
|
Cocrystal Pharma, Inc.
Feedback provides greater clarity on regulatory requirements for planned Phase 2b trial BOTHELL, Wash., March 19, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or...
Processa Successfully Identifies Next Generation Capecitabine Dosage Regimens for Phase 2B Trial
01. November 2022 08:30 ET
|
Processa Pharmaceuticals, Inc.
Next Generation Capecitabine (NGC) Dosage Regimens Have Been Identified In The Ongoing Phase 1B Trial With Potentially Better Safety And Efficacy Profiles Than Existing Chemotherapy These NGC...